Form 4: Rani Therapeutics Holdings CEO Buys Shares
Insider Transaction (Form 4)
Talat Imran, Chief Executive Officer and a Director of Rani Therapeutics Holdings, Inc., purchased 35,000 shares of common stock on July 17, 2026 for $0.72 per share.
Summary
- Open-market purchase: acquired 35,000 Class A Common Stock at $0.72 ($25,193) on July 17, 2026; holds 469,736 after (Direct).
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a bullish signal: an insider made an open-market purchase of $25,193, committing personal capital to the stock.
Insider Transactions
Talat Imran — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-17 | Open-market purchase | Class A Common Stock | 35,000 | $1 | $25.2K | 469,736 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-17 | Open-market purchase (35,000 shares) |
Keywords
insider transaction, Form 4, RANI, Rani Therapeutics Holdings, Inc., bullish, Talat Imran
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.